2Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattractant protein-1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum, 2003, 48: 2555-2566.
3Wada T, Yokoyama H, Su S, et al. Monitoring urinary levels of monocyte chemotactic and activation factor reflects disease activity of lupus nephritis. Kidney Int, 1996, 49: 761-767.
4Austin HA, Muenz LR, Joyce KM, et al. Prognostic factor in lupus nephritis. Am J Med, 1993, 75: 382-386.
5Gesualdo L, Grandaliano G. Monocyte recruitment in cryoglobulin mice membranoproliferative glomerulonephritis: a patho genetic role for monocyte chemotactic peptide-1. Kidney Int,1997, 51: 155-163.
6Wada T, Furuichi K, Segawa-Takeada C, et al. MIP-la and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int, 1999, 56: 995-1003.
7Hora K, Satriano JA, Santiago A, et al. Receptors for IgG complexes activate synthesis of monocyte chemoattractant peptide 1 and colony-stimulating factor 1. Proc Natl Acad Sci USA, 1992, 89: 1745-1749.
8Openheim JJ, Murphy WJ, Chertox O. Prospects for cytokine and chemokine biotherapy. Clin Cancer Res, 1997, 3: 2682-2686.
9Bombardier C,Gladman DD,Urowitz MB,et al.Derivation of the SLEDAI:a disease activity index for lupus patients.Arthritis Rheum,1992,35:630-640.
10Jacobi AM,Rohde W.Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but mot form healthy controls.Ann Rheum Drs,2001,60:242-247.
